BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:17 PM
 | 
Sep 28, 2012
 |  BC Extra  |  Company News

Subcutaneous Velcade approved in Europe for MM

The European Commission approved a subcutaneous formulation of Velcade bortezomib from Johnson & Johnson (NYSE:JNJ) to treat multiple...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >